bioAffinity Technologies, Inc. 8-K

What Happened
bioAffinity Technologies, Inc. (a Delaware corporation) announced on March 10, 2026 that it has begun its planned large-scale, longitudinal clinical study of CyPath® Lung, the company’s noninvasive diagnostic test for detecting early-stage lung cancer. The company filed an 8-K and attached the press release as Exhibit 99.1.

Key Details

• Date filed: March 10, 2026 (8-K reporting Other Events).
• Product: CyPath® Lung — a noninvasive diagnostic test intended to detect early-stage lung cancer.
• Activity: Initiation of a planned large-scale, longitudinal clinical study to generate clinical data.
• Press release: Attached to the 8-K as Exhibit 99.1 and incorporated by reference.

Why It Matters
Starting a large-scale, longitudinal clinical study is an important operational milestone: it is the process by which the company gathers the clinical data needed to assess performance, support potential regulatory submissions, and advance commercialization efforts. For investors, this filing signals that bioAffinity is moving forward with clinical validation of its diagnostic technology; watch for future updates on enrollment, study milestones and results, which could affect the company’s clinical and commercial timeline.